Renal function evaluation in patients with American Cutaneous Leishmaniasis after specific treatment with pentavalent antimonial

BMC Nephrology

Elizabeth F Daher¹  Alexandre B Libório⁶  Geraldo B Silva Junior⁶  Lúcia C Andrade¹  Antônio C Seguro¹  Talita R Sanches³  Alice Mc Martins²  Rosa Ms Mota⁵  Cláudio G Lima⁴  Rodrigo A Oliveira⁴ 

[1] Brazilian National Research Council (CNPq), São Paulo, Brazil;School of Pharmacy, Federal University of Ceará, Fortaleza, Ceará, Brazil;Division of Nephrology, School of Medicine, University of São Paulo, São Paulo, Brazil;Department of Internal Medicine, School of Medicine, Federal University of Ceará, Campus Cariri, Rua Divino Salvador, 284, Centro, Barbalha, Ceará, Brazil, CEP-63180-000;Department of Statistics, Sciences Center, Federal University of Ceará, Fortaleza, Ceará, Brazil;School of Medicine, Health Sciences Center, University of Fortaleza, Fortaleza, Ceará, Brazil

关键词: Treatment;    Tubular defects;    Renal function;    American cutaneous leishmaniasis;   

Others  :  1083169
DOI  :  10.1186/1471-2369-13-44

 received in 2011-11-24, accepted in 2012-06-14,  发布年份 2012

【 摘 要 】

Background

Renal evaluation studies are rare in American Cutaneous Leishmaniasis (ACL). The aim of this study is to investigate whether specific treatment reverts ACL-associated renal dysfunction.

Methods

A prospective study was conducted with 37 patients with ACL. Urinary concentrating and acidification ability was assessed before and after treatment with pentavalent antimonial.

Results

The patients mean age was 35.6 ± 12 years and 19 were male. Before treatment, urinary concentrating defect (U/P_osm <2.8) was identified in 27 patients (77%) and urinary acidification defect in 17 patients (46%). No significant glomerular dysfunction was observed before and after specific ACL treatment. There was no reversion of urinary concentrating defects, being observed in 77% of the patients before and in 88% after treatment (p = 0.344). Urinary acidification defect was corrected in 9 patients after treatment, reducing its prevalence from 40% before to only 16% after treament, (p = 0.012). Microalbuminuria higher than 30 mg/g was found in 35% of patients before treatment and in only 8% after treatment. Regarding fractional excretion of sodium, potassium, calcium, phosphorus and magnesium, there was no significant difference between pre and post-treatment period.

Conclusion

As previously described, urinary concentrating and acidification defects were found in an important number of patients with ACL. Present results demonstrate that only some patients recover urinary acidification capacity, while no one returned to normal urinary concentration capacity.

【 授权许可】

   
2012 Oliveira et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Goto H, Lindoso JAL: Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010, 8:419-433.
• [2]Barral B, Pedral-Sampaio D, Grimaldi G, Momen H, Mc Mahon-Pratt D, Ribeiro de Jesus A, Almeida R, Badaró R, Barral-Neto M, Carvalho EM, Johnson WD: Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg 1991, 44:536-546.
• [3]Grimaldi G, Mc-Mahon-Pratt D, Sun T: Leishmaniasis and its etiologic agents in the New World: an overview. Prog Clin Parasitol 1991, 2:73-118.
• [4]Gontijo B, Carvalho MLR: Leishmaniose Tegumentar Americana. Rev Soc Bras Med Trop 2003, 36:71-80.
• [5]Desjeux P: Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004, 27:305-318.
• [6]Roberts LJ, Handeman E, Foote SJ: Leishmaniasis. Br Med J 2000, 321:801-804.
• [7]Salgado-Filho N, Ferreira TM, Costa JM: Envolvimento da função renal em pacientes com leishmaniose visceral (calazar). Rev Soc Bras Med Trop 2003, 36:217-221.
• [8]Chaigne V, Knefati Y, Lafarge R, Bronner J, MC Gregor B, Fouque B, Sabatier JC: A patient with visceral leishmaniasis and acute renal failure in necrotizing glomerulonephritis. Nephrologie 2004, 25:179-183.
• [9]Duvic C, Nedelec G, Debord T, Herody M, Didelot F: Important parasitic nephropathies: update from recent literature. Nephrologie 1999, 20:65-74.
• [10]Oliveira MJC, Silva Júnior GB, Abreu KLS, Rocha NA, Garcia AVV, Franco LFLG, Mota RMS, Libório AB, Daher EF: Risk factors for acute kidney injury in visceral leishmaniasis. Am J Trop Med Hyg 2010, 83:449-453.
• [11]Councilman WT: Acute interstitial nephritis. J Experiment Med 1988, 3:393-420.
• [12]Cucé LC, Belda J, Dias W: Nephrotoxicyty to Glucantime® in the treatment of leishmaniasis. Rev Inst Med Trop S Paulo 1990, 32:249-251.
• [13]Duarte MIS, Silva MRR, Gotto H, Nicodemo EL, Amato-Neto V: Interstitial nephritis in human kala-azar. Trans R Soc Trop Med Hyg 1983, 77:531-537.
• [14]Lima Verde EM, Lima Verde FAA, Lima Verde FA, Silva Júnior GB, Daher EF: Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study on 50 patients from Brazil. J Nephrol 2007, 20:432-438.
• [15]Rodrigues MLO, Costa RS, Souza CS, Fossi NT, Roselino AMF: Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev Inst Med Trop S Paulo 1999, 41:33-37.
• [16]Oliveira RA, Diniz LFB, Teotonio LO, et al.: Renal tubular dysfunction in patients with American cutaneous leishmaniasis. Kidney Int 2011, 80:1099-1106.
• [17]Abadir A, Patel A, Haider S: Systemic therapy of new world cutaneous leishmaniasis: a case report and review article. Can J Infect Dis Med Microbiol 2010, 21:e79-e83.
• [18]Dutra M, Martinelli R, de Carvalho EM, et al.: Renal involvement in visceral leishmaniasis. Am J Kidney Dis 1985, 6:22-27.
• [19]Daher EF, Rocha NA, Oliveira MJ, Franco LF, Oliveira JL, Silva Junior GB, Abreu KL, Henn GA, Martins AM, Libório AB: Renal function improvement with pentavalent antimonial agents in patients with visceral leishmaniasis. Am J Nephrol 2011, 33:332-336.
• [20]Elnojomi N, Musa AM, Younis BM, Elfaki M, EL-Hassan AM, Khalil E: Surrogate markers of subtle renal injury in patients with visceral leishmaniasis. Saudi J Kidney Dis Transpl 2010, 21:872-875.
• [21]Oliveira RA, Silva GB, Souza CJ, et al.: Evaluation of renal function in leprosy: a study of 59 consecutive patients. Nephrol Dial Transplant 2008, 23:256-262.
• [22]Kirsztajn GM, Nishida SK, Silva MS, Ajzen H, Pereira AB: Renal abnormalities in Leprosy. Nephron 1993, 65:381-384.
• [23]Sampaio RNR, Paula CDR, Sampaio JHD, Furtado RS, Leal PP, Rosa TT, Rodrigues MR, Veiga JPR: Avaliação da tolerância e nefrotoxicidade do antimonial pentavalente administrado na dose de 40 mg Sbv/kg/dia por 30 dias na forma cutânea-mucosa de leishmaniose. Rev Soc Bras Med Trop 1997, 30:457-467.
• [24]Veiga JPR, Khanan R, Rosa TT, Junqueira LF, Brant PC, Raick AN, Friedman H, Marsden PD: Pentavalent antimonial nephrotoxicity in the rat. Rev Inst Med Trop S Paulo 1990, 32:304-309.